Climb Bio Total Assets 2021-2024 | CLYM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Climb Bio total assets from 2021 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Climb Bio total assets from 2021 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.4B
Vertex Pharmaceuticals (VRTX)	$125.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$106.8B
Gilead Sciences (GILD)	$105.9B
CSL (CSLLY)	$97.5B
GSK (GSK)	$81.1B
Alnylam Pharmaceuticals (ALNY)	$36.4B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.6B
Biogen (BIIB)	$27.9B
Illumina (ILMN)	$23.7B
Moderna (MRNA)	$22.2B
BeiGene (BGNE)	$22.1B
Genmab (GMAB)	$15.7B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$13.1B
Insmed (INSM)	$12.9B
Vaxcyte (PCVX)	$12.6B
Incyte (INCY)	$12.6B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.7B
QIAGEN (QGEN)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Revolution Medicines (RVMD)	$8.2B
Repligen (RGEN)	$8B
Intra-Cellular Therapies (ITCI)	$7.8B
Ascendis Pharma (ASND)	$7.8B